ISO 13485:2016 vs. FDA QMSR: What Changed and Why It Matters

On February 2, 2026, the U.S. Food and Drug Administration (FDA) implemented the Quality Management System Regulation (QMSR), replacing the long-standing Quality System Regulation (QS Regulation, 21 CFR Part 820). This represents one of the most significant changes to FDA medical device oversight in decades.

What is QMSR?

The QMSR incorporates ISO 13485:2016 by reference into the U.S. regulatory framework. This means that instead of maintaining a separate FDA-specific quality system, manufacturers can now align their quality management system with ISO 13485 and meet FDA requirements through that framework, supplemented by FDA-specific requirements.

Key Differences Between QS Regulation and QMSR

FDA-Specific Requirements Retained

While QMSR aligns with ISO 13485, certain FDA-specific requirements remain outside the scope of ISO 13485 and must still be met. These include:

Establishment Registration and Device Listing: 21 CFR Part 807

Medical Device Reporting (MDR): 21 CFR Part 803

Reports of Corrections and Removals: 21 CFR Part 806

Unique Device Identification (UDI): 21 CFR Part 830

Labeling Requirements: 21 CFR Part 801

Practical Implications

For manufacturers already certified to ISO 13485, the transition to QMSR is largely a matter of documenting how their existing system meets FDA-specific requirements. For manufacturers accustomed only to the QS Regulation, the shift requires alignment with ISO 13485's process-based approach and greater emphasis on risk management throughout the product lifecycle.

At Veritas Quality Solutions, we help manufacturers bridge the gap between ISO 13485 and QMSR, ensuring your quality management system satisfies both international and U.S. requirements efficiently.